Heart rate-adjusted PR as a prognostic marker of long-term ventricular arrhythmias and cardiac death in ICD/CRT-D recipients

Yu-Qiu LI1, Shuang ZHAO1, Ke-Ping CHEN1, Yang-Gang SU2, Wei HUA1, Si-Lin CHEN3, Zhao-Guang LIANG4, Wei XU5, Yan DAI1, Xiao-Han FAN1, Shu ZHANG1

1State Key Laboratory of Cardiovascular Disease, Arrhythmia Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China
3Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangzhou, China
4Department of Cardiology, First Affiliated Hospital of Harbin Medical University, Harbin, China
5Department of Cardiology, Nanjing Drum Tower Hospital, Nanjing, China

Abstract

Objective: To evaluate the PR to RR interval ratio (PR/RR, heart rate-adjusted PR) as a prognostic marker for long-term ventricular arrhythmias and cardiac death in patients with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy with defibrillators (CRT-D).

Methods: We retrospectively analyzed data from 428 patients who had an ICD/CRT-D equipped with home monitoring. Baseline PR and RR interval data prior to ICD/CRT-D implantation were collected from standard 12-lead electrocardiograph, and the PR/RR was calculated. The primary endpoint was appropriate ICD/CRT-D treatment of ventricular arrhythmias (VAs), and the secondary endpoint was cardiac death.

Results: During a mean follow-up period of 38.8 ± 10.6 months, 197 patients (46%) experienced VAs, and 47 patients (11%) experienced cardiac death. The overall PR interval was 160 ± 40 ms, and the RR interval was 866 ± 124 ms. Based on the receiver operating characteristic curve, a cut-off value of 18.5% for the PR/RR was identified to predict VAs. A PR/RR ≥ 18.5% was associated with an increased risk of VAs (hazard ratio (HR) = 2.243, 95% confidence interval (CI) = 1.665–3.022, P < 0.001) and cardiac death (HR = 2.358, 95%CI = 1.240–4.483, P = 0.009) in an unadjusted analysis. After adjustment in a multivariate Cox model, the relationship remained significant among PR/RR ≥ 18.5%, VAs (HR = 2.230, 95%CI = 1.555–2.825, P < 0.001) and cardiac death (HR = 2.105, 95%CI = 1.101–4.025, P = 0.024).

Conclusions: A PR/RR ≥ 18.5% at baseline can serve as a predictor of future VAs and cardiac death in ICD/CRT-D recipients.

Keywords: Implantable cardioverter defibrillator; PR interval; RR interval; Ventricular arrhythmias

1 Introduction

Sudden cardiac death (SCD) is the leading cause of cardiovascular mortality. Ventricular arrhythmias (VAs) are the main cause of SCD and account for 75% to 80% of these deaths[1,2]. Thus, it is important to identify high risk factors for VAs. Previous studies have found that faster heart rates (shorter RR intervals) were associated with SCD and other adverse outcomes in the general population as well as in patients with implantable cardioverter defibrillators (ICDs).[3,4]

The classification of the PR interval as a risk factor for clinical outcomes is controversial. Previous studies demonstrated that PR interval prolongation is associated with an increased risk of arrhythmia events and heart disease and therefore a poor prognosis.[5,6] Recent studies focusing on the association between the PR interval and cardiac resynchronization therapy (CRT) also concluded that PR interval prolongation can be a marker of heart failure hospitalization and death.[7–9] However, most recently, Senfield, et al.[10] demonstrated that the baseline PR interval did not affect clinical outcomes or reverse remodeling with CRT in mild heart failure. In an analysis from the COMPANION (Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure) trial, Olshansky, et al.[11] demonstrated that as a continuous variable, the PR interval did not predict outcomes. Outcomes after CRT were similar in the groups with normal and prolonged PR intervals.[11] Notably, the PR in-
terval was not adjusted for heart rate in these studies, as previous studies have not examined the predictive ability of heart rate-adjusted PR. Therefore, this study evaluates the PR to RR interval ratio (PR/RR, heart rate-adjusted PR) as a prognostic marker for long-term VAs and cardiac death.

2 Methods

We retrospectively analyzed archived HM transmissions data from the Study of Home Monitoring System Safety and Efficacy in Cardiac Implantable Electronic Device-Implantable Patients (SUMMIT) registry in China. All participants provided written informed consent, and the study protocol was approved by the hospital ethics committees.

2.1 Study population and device settings

We studied 428 patients who underwent ICD/CRT-D implantation between February 2009 and August 2014 and met the selection criteria. Before ICD/CRT-D implantation, a standard 12-lead resting electrocardiograph (ECG) at a paper speed of 25 mm/s was performed on each patient. The PR and RR intervals were transcribed from the computer interpretation of the ECG. All the measurements were validated by an investigator. Baseline PR and RR interval data from ECG were collected, and the PR/RRs was then calculated. The recorded demographic characteristics included age, sex, and body mass index (BMI). Before ICD/CRT-D implantation, baseline characteristics were obtained from the patients’ medical records. The program settings were as follows: the basic lower rate was 40–70 beats/min, the ventricular tachycardia (VT) detection rate was 140 beats/min, the ventricular fibrillation (VF) detection rate was 200 beats/min, and the therapy parameters were programmed according to the patient’s condition. To provide continuous patient monitoring, all devices were programmed to HM “on”. The data manager collected follow-up data. VAs were identified from the stored transmitted data. The clinicians assessed intracardiac electrograms to confirm the occurrence of VAs. All the VAs were validated by adjudicating the investigator again. The data manager, clinicians and adjudicating investigator were blind to the study. Mistaken identification events were excluded.

2.2 Selection criteria

The inclusion criteria were (1) patients aged ≥ 18 years, patients with an ICD/CRT-D device (Biotronic, Germany) equipped with HM that could transmit data daily, and (3) patients with recorded PR and RR intervals prior to ICD/CRT-D implantation.

The exclusion criteria were patients with atrial fibrillation (AF), liver failure, significant renal impairment, and grade III atrioventricular block.

2.3 Endpoints

The primary endpoint was appropriate ICD/CRT-D therapy of VAs. Routine follow-up was carried out, and if the patient’s transmission was disrupted, the condition of the patient was evaluated by follow-up phone calls. If the patient died, the date and cause of death were confirmed by contacting the patient’s family or reviewing the death certificate. The secondary endpoint was cardiac death.

2.4 Statistical analysis

We used the mean ± SD as the descriptive statistics for continuous variables and the number and percentage as the descriptive statistics for categorical variables. Differences between each group were compared using Student’s t-test for continuous variables and Pearson’s $X^2$ test for categorical variables as appropriate. The $P$ value was calculated when comparing two groups. A two-sided $P$ value < 0.05 was considered statistically significant. To evaluate the discriminatory ability of the PR/RR for VAs, we plotted receiver operating characteristic curves and obtained a cut-off value for quantitative variables. The categories of PR/RR ≥ 18.5% and PR/RR < 18.5% were used for the calculations performed. We used Kaplan-Meier survival curves to assess the survival time from the date of ICD/CRT-D implantation to the dates of VAs and cardiac deaths. The log-rank test (univariate analysis) was performed to test the significance of differences between the survival curves. We used univariate binary Cox regression analysis to examine the relationship between baseline characteristics and endpoints. Hazard ratios (HRs) and 95% CIs were calculated for each variable. For the multivariate Cox model, variables that had a statistical significance at a $P$ value < 0.05 were chosen. The covariates included for adjustment were age, PR interval, QT interval, QRS duration, heart rate, CRT-D presence, New York Heart Association (NYHA) classification, left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDD), β-blocker and amiodarone use, diabetes mellitus and hypertension.

All statistical analyses were performed using SPSS Statistics version 22.0 (IBM Corp., Armonk, New York) and GraphPad Prism software version 6.0 (GraphPad Software, La Jolla, California).

3 Results

3.1 Baseline characteristics

A total of 428 patients (320 males) with an average age of 58.6 ± 14.1 years were analyzed. The overall PR interval was
160 ± 40 ms, and the RR interval was 866 ± 124 ms. All eligible patients were grouped by PR/RR with a cut-off value of 18.5%. Cumulative hazard functions were significantly different between patients with a PR/RR ≥ 18.5% and those with a PR/RR < 18.5% (P < 0.001) (Figure 1). Baseline demographic and clinical characteristics between the two groups are detailed in Table 1. Compared with patients with a PR/RR < 18.5%, those with a PR/RR ≥ 18.5% were more likely to be male (P = 0.035) and have an implanted CRT-D (P = 0.001), lower LVEF (P < 0.001), shorter QT interval (P < 0.001), longer QRS duration (P = 0.001) and worse NYHA classification (P < 0.001). Hypertension (P = 0.016), diabetes mellitus (P = 0.002) and dilated cardiomyopathy (P < 0.001) were more prevalent in patients with PR/RR ≥ 18.5%.

Figure 1. ROC curve with a cut-off value of 18.5% for PR/RR to predict VAs, P < 0.001. ROC curve: receiver operating characteristic curve; VAS: ventricular arrhythmias.

Table 1. Baseline characteristics vs. admission PR/RR.

| Demographics          | Total population (n = 428) | PR/RR ≥ 18.5% (n = 224) | PR/RR < 18.5% (n = 204) | P value |
|-----------------------|---------------------------|--------------------------|--------------------------|---------|
| Male sex              | 320 (74.8%)               | 177 (79.0%)              | 143 (70.1%)              | 0.035   |
| Age, yrs              | 58.65 ± 14.09             | 59.26 ± 13.34            | 57.97 ± 14.88            | 0.345   |
| BMI, kg/m²             | 23.49 ± 3.94              | 23.34 ± 3.87             | 23.66 ± 4.02             | 0.397   |
| NYHA Class III-IV, %  | 188 (43.9%)               | 121 (54.0%)              | 67 (32.8%)               | <0.001  |
| SBP, mmHg              | 123.87 ± 16.66            | 123.82 ± 16.56           | 123.93 ± 16.82           | 0.948   |
| DBP, mmHg              | 76.63 ± 10.98             | 76.35 ± 10.89            | 76.95 ± 11.10            | 0.570   |
| CRT-D                 | 119 (27.8%)               | 78 (34.8%)               | 41 (20.1%)               | 0.001   |
| Primary prevention     | 47 (11.0%)                | 26 (11.6%)               | 21 (10.3%)               | 0.757   |
| ECG                   |                           |                          |                          |         |
| PR interval, ms        | 160.8 ± 40.4              | 186.4 ± 33.4             | 132.8 ± 26.4             | <0.001  |
| RR interval, ms        | 865.9 ± 123.7             | 820.7 ± 109.8            | 915.6 ± 119.2            | <0.001  |
| QT interval, ms        | 705.1 ± 128.1             | 634.3 ± 99.9             | 782.8 ± 109.4            | <0.001  |
| QRS duration, ms       | 120.2 ± 32.9              | 125.4 ± 34.1             | 114.5 ± 30.5             | 0.001   |
| Echocardiography       |                           |                          |                          |         |
| LVEF, %                | 43.05 ± 15.80             | 40.42 ± 14.91            | 45.93 ± 16.28            | <0.001  |
| LVEDD, mm              | 57.99 ± 13.89             | 59.14 ± 13.72            | 56.71 ± 14.01            | 0.073   |
| Comorbidities          |                           |                          |                          |         |
| CHD                    | 100 (23.4%)               | 54 (24.1%)               | 46 (22.5%)               | 0.732   |
| IHD                    | 113 (26.4%)               | 56 (25.0%)               | 57 (27.9%)               | 0.511   |
| HBP                    | 134 (31.3%)               | 82 (36.6%)               | 52 (25.5%)               | 0.016   |
| DCM                    | 109 (25.5%)               | 79 (35.3%)               | 30 (14.7%)               | <0.001  |
| Valvular disease       | 2 (0.5%)                  | 1 (0.4%)                 | 1 (0.5%)                 | 1.000   |
| Diabetes               | 38 (8.9%)                 | 29 (12.9%)               | 9 (4.4%)                 | 0.002   |
| Stroke                 | 105 (24.5%)               | 51 (22.8%)               | 54 (26.5%)               | 0.431   |
| Meditation             |                           |                          |                          |         |
| Beta-blockers          | 140 (32.7%)               | 86 (38.4%)               | 54 (26.5%)               | 0.010   |
| Amiodarone             | 130 (30.4%)               | 81 (36.2%)               | 49 (24.0%)               | 0.008   |
| ACEI or ARB            | 237 (55.4%)               | 132 (58.9%)              | 105 (51.5%)              | 0.144   |
| Loop diuretic          | 114 (26.6%)               | 50 (22.3%)               | 64 (31.4%)               | 0.038   |

Data are presented as mean ± SD or n (%). ACEI/ARB: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; BMI: body mass index; CHD: coronary heart disease; DBP: diastolic blood pressure; DCM: dilated cardiomyopathy; ECG: electrocardiograph; HBP: high blood pressure; IHD: ischemic heart disease; LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association; SBP: systolic blood pressure.
3.2 A PR/RR ≥ 18.5% at baseline is a predictor of future VAs and cardiac death in ICD/CRT-D recipients

The clinical outcomes of patients depended on PR/RR, as shown in Table 2. During a mean follow-up of 38.8 ± 10.6 months, 197 patients (46%) experienced VAs, and 47 patients (11%) experienced cardiac death. The incidence rates of VAs in patients with PR/RR ≥ 18.5% and PR/RR < 18.5% were 58.9% and 31.9% (*P* < 0.001), respectively. In addition, there were more cardiac deaths in patients with a PR/RR ≥ 18.5% than in patients with a PR/RR < 18.5% (34, 15.2% vs. 13, 6.4%, *P* = 0.005).

Estimated Kaplan-Meier curves were plotted to determine VAs and cardiac death among patients based on PR/RR intervals. Compared with patients with a PR/RR < 18.5%, patients with a PR/RR ≥ 18.5% had an increased cumulative incidence of VAs (*P* < 0.001) and cardiac death (*P* = 0.007) (Figure 2).

Table 2. Clinical outcomes of patients dependent on PR/RR.

| Overall | PR/RR ≥ 18.5% | PR/RR < 18.5% | *P* value |
|---------|--------------|---------------|-----------|
| VAs     | 197 (46%)    | 132 (58.9%)   | 65 (31.9%)| < 0.001 |
| Cardiac Death | 47 (11%) | 34 (15.2%) | 13 (6.4%) | 0.005 |

Data are presented as n (%). VAs: ventricular arrhythmias.

In univariate Cox proportional hazard models, PR/RR ≥ 18.5% was associated with an increased risk of VAs (HR = 2.243, 95%CI = 1.665–3.022, *P* < 0.001) and cardiac death (HR = 2.358, 95%CI = 1.240–4.483, *P* = 0.009). Upon adjustment in a multivariate model, PR/RR ≥ 18.5% remained an independent predictor of VAs (HR = 2.096, 95%CI = 1.555–2.825, *P* < 0.001) and cardiac death (HR = 2.105, 95%CI = 1.101–4.025, *P* = 0.024) (Table 3). The covariates included for adjustment were age, PR interval, QT interval, QRS duration, heart rate, CRT-D presence, NYHA classification, LVEF, LVEDD, β-blocker and amiodarone use, diabetes mellitus, and hypertension.

3.3 Baseline heart rate, PR interval and long-term outcomes

In univariate Cox proportional hazard models, baseline heart rate was associated with an increased risk of VAs (HR = 1.019, 95%CI = 1.006–1.032, *P* = 0.004) and cardiac death (HR = 1.026, 95%CI = 1.002–1.051, *P* = 0.031). Upon adjustment in a multivariate model, baseline heart rate remained an independent predictor of VAs (HR = 1.018, 95%CI = 1.006–1.031, *P* = 0.004) (Table 3). In univariate Cox proportional hazard models, the PR interval was associated with an increased risk of VAs (HR = 1.006, 95%CI = 1.002–1.009, *P* = 0.002) but not cardiac death (HR = 1.007, 95%CI = 1.000–1.014, *P* = 0.062). Upon adjustment in a multivariate model, the PR interval

Table 3. Univariate and multivariate Cox proportional hazard models according to PR/RR as a category.

| PR/RR | HR   | 95%CI     | *P* value |
|-------|------|-----------|-----------|
| Univariate | VAs  | 2.243     | 1.665–3.022 | < 0.001 |
| Multivariate | VAs | 2.096     | 1.555–2.825 | < 0.001 |
| PR interval | VAs  | 1.006     | 1.002–1.009 | 0.002 |
| Multivariate | VAs | 1.006     | 1.003–1.010 | < 0.001 |

VAs: ventricular arrhythmias.
remained an independent predictor of VAs (HR = 1.006, 95% CI = 1.003–1.010, \( P < 0.001 \)) (Table 3).

4 Discussion

The significant findings of this analysis are summarized as follows: patients with a baseline PR/RR value of \( \geq 18.5\% \) exhibited a higher incidence of VAs and cardiac death independent of baseline PR intervals and RR intervals. Moreover, baseline heart rate is associated with a higher incidence of VAs and cardiac death. Finally, the baseline PR interval is a significant risk factor for VAs but not cardiac death.

The inverse correlation between heart rate and PR interval is widely recognized, with PR intervals shortening as heart rates increase.\[12,13\] Without rate adjustment, PR intervals are 10 ms or more at higher and lower heart rates.\[14\] Therefore, the significance of rate-adjusted PR intervals is evident. The PR interval was an independent risk factor for VAs and a borderline significant risk factor for cardiac death (\( P = 0.062 \)) in this study. However, after adjusting for heart rate, the PR interval was associated with a high risk of both VAs and cardiac death. There are at least two possible explanations for the relationship between high PR/RR ratios and the prevalence of VAs and cardiac death.

First, this relationship may be associated with PR interval prolongation. Two large community-based studies (the Framingham Heart Study and the Atherosclerosis Risk in Community Study) both showed that PR interval prolongation was associated with increased risks of arrhythmic events and death.\[5,15\] Prolongation of the PR interval can be caused by an organic lesion or a functional disorder related to the autonomic nervous system, and it is associated with a number of factors that have been proven to be associated with VAs and cardiac death (including ischemic heart disease, AF, diabetes mellitus, conduction tissue fibrosis and autonomic tone) and may be a marker for increased ventricular fibrosis and scarring.\[5,8\] Recently, Chan, et al.\[16\] demonstrated that prolongation of the PR interval is associated with endothelial dysfunction, which has already been demonstrated as one of the mechanisms of ventricular tachycardia\[17\] and other cardiovascular events.

Second, the ratio of PR to RR intervals was calculated with baseline PR and RR intervals. The higher the ratio is, the longer the PR interval and/or the shorter the RR interval. However, when the heart rate is faster, the RR interval is shorter. This study found baseline heart rate to be a significant predictor of VAs and cardiac death, which is similar to previous findings. There have been several reports that increased heart rate is associated with increased risks of VAs, mortality, and heart failure hospitalization.\[3,4,18\] The mechanisms involved in include greater heart rate increases, vascular oxidative stress, decreased endothelial function restoration and autonomic nervous system dysregulation.\[4\] A disassociation between the PR interval and RR interval may be an indicator of autonomic dysfunction. In most cases, a prolonged PR interval is due to prolonged conduction in the AV node, which is profoundly influenced by the autonomic nervous system. Sympathetic nervous activation results in a decrease in PR intervals, whereas parasympathetic nerve activation results in an increase in PR intervals.\[19\] Shortened RR intervals reflect sympathetic activation and/or vagal withdrawal at the sino-atrial node level.\[20\] The dissociation between the PR interval and RR interval may be a novel marker of cardiac autonomic dysfunction and, thus, a novel independent predictor of VAs and cardiac death. There are several significant implications of these findings; specifically, unlike previous studies, we examine the predictive ability of rate-adjusted PR intervals. Moreover, PR/RR \( \geq 18.5\% \) at baseline can serve as a predictor of future VAs and cardiac death in ICD/CRT-D recipients. This novel marker may provide an opportunity to manage ICD patients at risk for cardiac events. In clinical practice, optimal medication is needed to control heart rate more strictly for these patients. Additionally, dual chamber pacemaker or CRT may be more suitable for patients who need ventricular pacing to shorten the AV interval by programming. Finally, this information will be helpful in screening patients at a high risk for cardiac events and may help clinicians refer high-risk primary prevention patients for ICD or CRT-D.

4.1 Study limitations

Our study has several limitations. First, we used a single 12-lead ECG, not an average of multiple ECGs or data from a 24-h Holter. Due to the absence of baseline Holter data, we did not assess the relationship between heart rate variability and PR/RR. Furthermore, both the RR and PR intervals have circadian variation and may change with time. Many potential unknown confounding factors may be unaddressed in this study. Finally, this study was retrospective. Thus, a prospective analysis with a longer observational period should be performed to validate the results.

4.2 Conclusions

A PR/RR \( \geq 18.5\% \) at baseline can serve as a predictor of future VAs and cardiac death in ICD/CRT-D recipients. This marker may provide an opportunity to manage ICD patients at risk for cardiac events, and it will be helpful in screening patients at a high risk for cardiac events.

http://www.jgc301.com; jgc@mail.sciencep.com | Journal of Geriatric Cardiology
Acknowledgments

We thank Hui Li (Beijing Hui Kang Xin Technology Co., Ltd.) and his group for data processing and monitoring. The authors have declared no conflicts of interest.

References

1. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989; 117: 151–159.
2. Hayashi M, Shimizu W, Albert CM. The spectrum of epidemiology underlying sudden cardiac death. Circ Res 2015; 116: 1887–1906.
3. Ahmadi-Kashani M, Kessler DJ, Day J, et al. Heart rate predicts outcomes in an implantable cardioverter-defibrillator population. Circulation 2009; 120: 2040–2045.
4. Hoogwegt MT, Theuns DA, Pedersen SS, Kupper N. Long-term mortality risk in patients with an implantable cardioverter-defibrillator: influence of heart rate and QRS duration. Int J Cardiol 2014; 175: 560–564.
5. Cheng S, Keyes MJ, Larson MG, et al. Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA 2009; 301: 2571–2577.
6. Kwok CS, Rashid M, Beynon R, et al. Prolonged PR interval, first-degree heart block and adverse cardiovascular outcomes: a systematic review and meta-analysis. Heart 2016; 102: 672–680.
7. Januszkievicz L, Vegh E, Borgquist R, et al. Prognostic implication of baseline PR interval in cardiac resynchronization therapy recipients. Heart Rhythm 2015; 12: 2256–2262.
8. Friedman DJ, Bao H, Spatz ES, et al. Association between a prolonged PR interval and outcomes of cardiac resynchronization therapy: a report from the national cardiovascular data registry. Circulation 2016; 134: 1617–1628.
9. Rickard J, Karim M, Baranowski B, et al. Effect of PR interval prolongation on long-term outcomes in patients with left bundle branch block vs. non-left bundle branch block morphologies undergoing cardiac resynchronization therapy. Heart Rhythm 2017; 14: 1523–1528.
10. Senfield J, Daubert C, Abraham WT, et al. The impact of the PR interval in patients receiving cardiac resynchronization therapy. JACC Clin Electrophysiol 2017; 3: 818–826.
11. Olshansky B, Day JD, Sullivan RM, et al. Does cardiac resynchronization therapy provide unrecognized benefit in patients with prolonged PR intervals? The impact of restoring atrioventricular synchrony: an analysis from the COMPANION Trial. Heart Rhythm 2012; 9: 34–39.
12. Atterhog JH, Loogna E. P-R interval in relation to heart rate during exercise and the influence of posture and autonomic tone. J Electrocardiol 1977; 10: 331–336.
13. Danter WR, Carruthers SG. The heart rate-PR interval relationship: a model for evaluating drug actions on SA and AV nodal function. Br J Clin Pharmacol 1990; 30: 490–492.
14. Soliman EZ, Rautaharju PM. Heart rate adjustment of PR interval in middle-aged and older adults. J Electrocardiol 2012; 45: 66–69.
15. Soliman EZ, Prineas RJ, Case LD, et al. Ethnic distribution of ECG predictors of atrial fibrillation and its impact on understanding the ethnic distribution of ischemic stroke in the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2009; 40: 1204–1211.
16. Chan YH, Siu CW, Yiu KH, et al. Abnormal vascular function in PR-interval prolongation. Clin Cardiol 2011; 34: 628–632.
17. Hassanabad ZF, Furman BL, Parratt JR, Aughey E. Coronary endothelial dysfunction increases the severity of ischaemia-induced ventricular arrhythmias in rat isolated perfused hearts. Basic Res Cardiol 1998; 93: 241–249.
18. Cale R, Mendes M, Brito J, et al. Resting heart rate is a powerful predictor of arrhythmic events in patients with dilated cardiomyopathy and implantable cardioverter-defibrillator. Rev Port Cardiol 2011; 30: 199–212.
19. Pirola FT, Potter EK. Vagal action on atrioventricular conduction and its inhibition by sympathetic stimulation and neuropeptide Y in anaesthetised dogs. J Auton Nerv Syst 1990; 31: 1–12.
20. Smith JH, Baumert M, Nalivaiko E, et al. Arousal in obstructive sleep apnoea patients is associated with ECG RR and QT interval shortening and PR interval lengthening. J Sleep Res 2009; 18: 188–195.